Expand LXRX Menu
LXRX MENU

LXRX Latest Press Releases

-- December 10, 2025 --

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 Globe Newswire 8:30 AM

-- December 5, 2025 --

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum Globe Newswire 8:30 AM

-- November 25, 2025 --

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences Globe Newswire 8:30 AM

-- November 11, 2025 --

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference Globe Newswire 8:30 AM

-- November 8, 2025 --

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 Globe Newswire 2:30 PM

-- November 6, 2025 --

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates Globe Newswire 7:30 AM

-- November 4, 2025 --

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans Globe Newswire 8:30 AM

-- October 30, 2025 --

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 Globe Newswire 8:30 AM

-- October 14, 2025 --

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit Globe Newswire 8:00 AM

-- October 8, 2025 --

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain Globe Newswire 7:59 AM

-- September 22, 2025 --

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes Globe Newswire 4:00 PM

-- September 17, 2025 --

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings Globe Newswire 7:00 AM

-- September 11, 2025 --

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings Globe Newswire 8:30 AM

-- September 8, 2025 --

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes Globe Newswire 8:30 AM

-- September 4, 2025 --

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 Globe Newswire 8:30 AM

-- September 3, 2025 --

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 Globe Newswire 8:30 AM

-- September 2, 2025 --

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress Globe Newswire 8:30 AM

-- August 27, 2025 --

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences Globe Newswire 8:30 AM

-- August 6, 2025 --

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Globe Newswire 7:30 AM

-- July 31, 2025 --

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes